All Phenotypes Tg(CAG-cre/Esr1*)86Lbgn MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Nphs2^tm1Antc/Nphs2^tm3.1Antc Tg(CAG-cre/Esr1*)86Lbgn/0	involves: 129 * C57BL/6 * DBA	MGI:4847559
cn2	Nphs2^tm2.1Antc/Nphs2^tm3.1Antc Tg(CAG-cre/Esr1*)86Lbgn/0	involves: 129S2/SvPas * C57BL/6 * DBA	MGI:6316681

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:166320 )

• mice die 11 weeks after tamoxifen treatment

renal/urinary system

increased urine protein level ( J:166320 )

• after 4 weeks of tamoxifen treatment, mice develop nonselective proteinuria compared with control mice

albuminuria ( J:166320 )

• after 10 days of tamoxifen treatment

• after 2 weeks of nursing from mice fed tamoxifen

abnormal kidney morphology ( J:166320 )

• after 9 weeks, tamoxifen-treated mice exhibit progressive tubular injury with basement membrane thickening and interstitial fibrosis unlike similarly treated wild-type mice

podocyte foot process effacement ( J:166320 )

• tamoxifen-treated mice exhibit focal effacement at 1 and 2 weeks then diffuse effacement at 4 weeks unlike similarly treated wild-type mice

podocyte hypertrophy ( J:166320 )

• after 2 weeks of tamoxifen treatment, mice exhibit podocyte hypertrophy compared with similarly treated control mice

abnormal renal glomerulus morphology ( J:166320 )

• after 4 weeks, tamoxifen-treated mice exhibit glomerular pseudocrescents in some glomeruli unlike in similarly treated control mice

increased mesangial cell number ( J:166320 )

• mice nursed by dams fed tamoxifen exhibit lesions of mesangial proliferation compared with similarly treated controls

expanded mesangial matrix ( J:166320 )

• after 2 weeks of tamoxifen treatment, mice exhibit minimal mesangial matrix expansion compared with similarly treated control mice

glomerulosclerosis ( J:166320 )

• after 4 weeks of tamoxifen treatment, mice exhibit focal segmental glomerulosclerosis in many glomeruli with varying severity unlike in similarly treated control mice

• mice nursed by dams fed tamoxifen exhibit lesions of focal segmental glomerulosclerosis unlike similarly treated control mice

• glomerulosclerosis worsens by 6 weeks of tamoxifen treatment

• at or near death, tamoxifen-treated mice exhibit global scelrosis

renal interstitial fibrosis ( J:166320 )

• after 9 weeks in tamoxifen-treated mice

abnormal renal tubule morphology ( J:166320 )

• tamoxifen-treated mice exhibit tubulointerstitial injury with diffuse tubular dilation, tubular atrophy and necrosis, and proteinaceous casts unlike in similarly treated control mice

renal tubular necrosis ( J:166320 )

• in tamoxifen-treated mice

renal tubule atrophy ( J:166320 )

• in tamoxifen-treated mice

dilated renal tubule ( J:166320 )

• in tamoxifen-treated mice

renal cast ( J:166320 )

• in tamoxifen-treated mice

homeostasis/metabolism

increased circulating creatinine level ( J:166320 )

• after 6 weeks of tamoxifen treatment

increased blood urea nitrogen level ( J:166320 )

• after 6 weeks of tamoxifen treatment

increased circulating cholesterol level ( J:166320 )

• after 4 weeks of tamoxifen treatment

increased urine protein level ( J:166320 )

• after 4 weeks of tamoxifen treatment, mice develop nonselective proteinuria compared with control mice

albuminuria ( J:166320 )

• after 10 days of tamoxifen treatment

• after 2 weeks of nursing from mice fed tamoxifen

cardiovascular system

increased systemic arterial systolic blood pressure ( J:166320 )

• modestly after 4 weeks of tamoxifen treatment

cellular

increased mesangial cell number ( J:166320 )

• mice nursed by dams fed tamoxifen exhibit lesions of mesangial proliferation compared with similarly treated controls

renal tubular necrosis ( J:166320 )

• in tamoxifen-treated mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
nephrotic syndrome		DOID:1184		J:166320

Allelic Composition	Nphs2^tm2.1Antc/Nphs2^tm3.1Antc Tg(CAG-cre/Esr1*)86Lbgn/0
Genetic Background	involves: 129S2/SvPas * C57BL/6 * DBA

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nphs2^tm2.1Antc mutation (0 available); any Nphs2 mutation (30 available)
Nphs2^tm3.1Antc mutation (0 available); any Nphs2 mutation (30 available)
Tg(CAG-cre/Esr1*)86Lbgn mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

Nphs2^tm2.1Antc/Nphs2^tm3.1Antc Tg(CAG-cre/Esr1*)86Lbgn/0 mice develop focal-segmental glomerulosclerosis

mortality/aging

premature death ( J:245693 )

• the median survival of tamoxifen-treated mice is 12 weeks

growth/size/body

decreased body weight ( J:245693 )

• mice exhibit lower body weight from week 6 onward after tamoxifen treatment

cardiovascular system

increased systemic arterial blood pressure ( J:245693 )

• blood pressure moderately increases after tamoxifen treatment

homeostasis/metabolism

increased urine creatinine level ( J:245693 )

• mice exhibit increased creatinine levels within a few days of tamoxifen treatment

increased circulating cholesterol level ( J:245693 )

• mice exhibit hypercholesterolemia 4 weeks after tamoxifen induction

decreased circulating serum albumin level ( J:245693 )

• mice exhibit hypoalbuminemia 4 weeks after tamoxifen induction

increased urine protein level ( J:245693 )

• mice develop proteinuria within a few days of tamoxifen treatment which increases to a maximum 4-5 weeks after induction and thereafter decreases gradually but remains elevated compared to controls

renal/urinary system

increased urine creatinine level ( J:245693 )

• mice exhibit increased creatinine levels within a few days of tamoxifen treatment

increased urine protein level ( J:245693 )

abnormal podocyte foot process morphology ( J:245693 )

• foot processes are irregularly shaped one week after tamoxifen induction, progressing to effacement

fused podocyte foot processes ( J:245693 )

• foot processes are fused one week after tamoxifen induction progressing to global fusion and effacement

podocyte foot process effacement ( J:245693 )

• in tamoxifen treated mice

decreased podocyte number ( J:245693 )

• mice show reduced podocyte number per glomerulus starting at the end of the second week after tamoxifen induction (68% of controls) to 18% of controls at 12-16 weeks

increased renal glomerulus basement membrane thickness ( J:245693 )

• glomerular basement membrane is thickened in tamoxifen-induced mice

glomerulosclerosis ( J:245693 )

• mice exhibit early glomerular sclerosis form the first week after tamoxifen induction that progresses increases until week eight when 100% of glomeruli are partially or globally sclerosed

renal interstitial fibrosis ( J:245693 )

• mice develop severe interstitial fibrosis which is visible from the first week after tamoxifen induction and increase to 12% of the total kidney area in the course of the disease

renal tubule atrophy ( J:245693 )

• mice develop tubular atrophy that is visible from the first week after tamoxifen induction

decreased creatinine clearance ( J:245693 )

• mice exhibit diminished creatinine clearance 4 weeks after tamoxifen induction

kidney failure ( J:245693 )

• mice progress to renal failure after tamoxifen-induction

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
nephrotic syndrome		DOID:1184		J:245693

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/23/2024 MGI 6.23